Precision Oncology in Soft Tissue Sarcomas and Gastrointestinal Stromal Tumors

Surg Oncol Clin N Am. 2024 Apr;33(2):387-408. doi: 10.1016/j.soc.2023.12.018. Epub 2024 Jan 18.

Abstract

Soft tissue sarcomas (STSs), including gastrointestinal stromal tumors (GISTs), are mesenchymal neoplasms with heterogeneous clinical behavior and represent broad categories comprising multiple distinct biologic entities. Multidisciplinary management of these rare tumors is critical. To date, multiple studies have outlined the importance of biological characterization of mesenchymal tumors and have identified key molecular alterations which drive tumor biology. GIST has represented a flagship for targeted therapy in solid tumors with the advent of imatinib which has revolutionized the way we treat this malignancy. Herein, the authors discuss the importance of biological and molecular diagnostics in managing STS and GIST patients.

Keywords: Gastrointestinal stromal tumor; Precision medicine; Precision oncology; Sarcoma; Tumor biology.

Publication types

  • Review

MeSH terms

  • Gastrointestinal Stromal Tumors* / drug therapy
  • Gastrointestinal Stromal Tumors* / genetics
  • Humans
  • Imatinib Mesylate / therapeutic use
  • Precision Medicine
  • Sarcoma* / drug therapy
  • Sarcoma* / genetics
  • Sarcoma* / pathology
  • Sodium Tetradecyl Sulfate / therapeutic use
  • Soft Tissue Neoplasms*

Substances

  • Imatinib Mesylate
  • Sodium Tetradecyl Sulfate